Enzolytics Inc (ENZC)

[falon]

5 REASONS WHY ENZOLYTICS IS A COMPELLING CHOICE!


https://www.aviseanalytics.com/5-reasons-why-enzolytics-inc-is-a-compelling-choice/

!

11 JUN 5 REASONS WHY ENZOLYTICS IS A COMPELLING CHOICE!
Posted at 10:02h in Biotechnology by admin 0 Comments
14Likes
Share
Enzolytics Inc. (OTCPK: ENZC) is leveraging over 40 years of drug development experience to develop proprietary antiviral peptides and monoclonal antibodies for the treatment of Infectious Diseases. The Company is using a combination of patented-HIV therapeutics and an exclusive methodology, for creating fully human IgG1 monoclonal antibodies, which can target and neutralize HIV Virus to treat infectious diseases with non-toxic passive immunotherapy.

Enzolytics is committed to the development of proteins and monoclonal antibodies, which can combat a wide array of infectious diseases such as Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria, besides Rheumatoid Arthritis and some forms of cancer. The Company is extending its proprietary technology to create anti-SARS-CoV-2 (Coronavirus) monoclonal antibodies, intended for the treatment of COVID-19.

Enzolytics Inc. (OTCPK: ENZC)

Market Cap: $ 676.73M; Current Share Price: 0.278 USDChart
Data by YCharts

An Industry with Large Unmet Needs

Human Immunodeficiency Virus (HIV) compromises the body’s immunity by attacking CD4 cells (a type of T cell), exposing it to a host of infections and diseases and ultimately leading to the development of AIDS. According to data provided by Centres for Disease Control and Prevention, an estimated 1.1 million people in the U.S are afflicted with this disease and 1 in 7 or 15% of those affected are unaware of their condition. In 2017, over 38,739 people were diagnosed with HIV and 6 dependent areas and nearly 15,807 deaths were registered among people diagnosed with HIV.

Advances in treatment and care, such as development of antiretroviral therapy (ART), have increased the life expectancy of people diagnosed with HIV and helped arrest the disease from progressing to AIDS, with an estimated 20.9 million people on ART as of 2017. There is no cure for the disease as yet, with existing therapeutic options seeking to stop the progression of the disease and alleviating symptoms.

Antiretroviral Therapy can be categorised as highly active antiretroviral therapy (HAART) or combination antiretroviral therapy (cART), however they can cause adverse reactions, severe toxicity and exacerbate existing co-morbidities. Scientific advancements have led to the discovery and development of Protease Inhibitors, Integrase Inhibitors, Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Chemokine co-receptor antagonists and Entry inhibitors that seek to overcome the limitations of the existing treatment options.

According to a report by GlobalData, the global HIV market will reach $22.5 billion by 2025 growing at a CAGR of 3% from $16.3 billion in 2015.


Image Source: Company

A Key Collaboration with Intel Corporation

In May 2021, the Company published a white paper through a thought leadership collaboration with Intel Corporation (NASDAQ: INTC) titled “Optimizing Empathetic A.I. to Cure Deadly Diseases”. The paper highlights the Company’s use of Artificial Intelligence, which is a novel approach to assessing virus sequences so that the segments essential for a virus survival are promptly identified. Intel’s Empathetic A.I helps outsource healthcare related decisions to machines, thereby enabling healthcare practitioners to spend more time in developing relationships with patients. Furthermore, Intel’s Programmable Integrated Unified Memory Architecture (PIUMA) will speed up drug discoveries and predict virus mutations with great speed and accuracy.

Speaking on the collaboration with Intel, Charles Cotropia, CEO of Enzolytics, stated,

“We are honored and privileged to work with the preeminent international corporation Intel in a collaborative manner focused on the optimum way to advance healthcare using science and technology together. Combining science with technology will guarantee success.”

A Promising Therapeutic Candidate for HIV

The Company’s lead candidate is an anti-HIV therapeutic known as ITV-1, which is a suspension of Inactivated Pepsin Fragment (IPF) that has demonstrated the potential to strengthen the immune system and neutralize the HIV virus, in clinical studies conducted in the European Union. Enzolytics proprietary technology enables the creation of human cell lines that are capable of producing fully human monoclonal antibodies. CLONE 3, one of these antibodies has the potential to completely neutralize 95 percent of HIV-1 strains and viral subtypes.

Enzolytic’s portfolio of therapeutics may not only be used as immunotherapeutic treatment for HIV/AIDS but also serve as a prophylactic and therapeutic vaccine against HIV. The treatment offers significant improvement over existing therapies such as ARV, by demonstrating a better efficacy and non-toxicity, besides being for a shorter duration and cost effective.

Merger with BioClonetics Immunotherapeutics, Inc brings in a Synergistic Platform

In December 2020, the Company announced the completion of the merger with BioClonetics Immunotherapeutics, Inc. The Companies are now pursuing two diverse but complementary therapy platforms, namely antiviral peptide and fully human anti-monoclonal antibodies.

Speaking on the synergy of these two technologies Harry Zhabilov, CSO of Enzolytics, commented,

“The technologies of the combined entities will afford the Company the opportunity to unlock the potential of our HIV-AIDS treatments at a time when the seriousness of the disease is still a major concern given that the current form of treatment for HIV patients is antiretroviral treatment and where such treatment is only accessible to 40% of the 36 million peoples in the world infected by HIV – leaving 60% of the 36 million infected HIV patients with no treatment.”

The Company’s anti-HIV mAb in PBMC neutralization assays are in the final testing phase and will be followed by animal trials at the California National Primate Research Center, UC Davis (Davis, CA). In addition, Enzolytics is developing anti-SARS-Cov-2 (CoronaVirus) monoclonal antibodies, based on its research that there is a significant correlative structure between the HIV virus and the SARS-CoV-2 virus. The antibodies are intended to act as a therapeutic and produce a phage display anti-SARS-CoV-2 (CoronaVirus) vaccine.

Extensive Intellectual Property Rights Portfolio

Enzolytics has built a strong intellectual property rights portfolio with patents covering its technology related to peptide which cover Pepsin Fragment (IPF) identified and characterized by the amino acid sequence GDEPLENYLDTEYF and the Clone 3 cell line, fully human monoclonal antibodies (mAbs) that specifically target and neutralize the HIV-1 virus. The Company also has multiple patents pending covering the recombinant of the Clone 3 antibody and coverage of small molecules (mini-peptides) among others.

Key Takeaways

On June 7, the Company announced a protocol to produce therapeutics for HIV as well as existing and future pandemics, an outcome of its collaboration with Intel Corporation, which seeks to leverage Artificial Intelligence to aid discoveries and development in healthcare. The coloration extends to investigating the relationship and interaction between monoclonal antibodies with viruses in 3-dimensional matrices.

The Company has built multiple strategic research and development collaborations and partnerships and has currently set milestones, which are necessary to land partnerships with other biopharmaceutical companies, which have expressed interest in the Company’s technology and pipeline. Some of these milestones include Testing of anti-HIV Monoclonal Antibodies at University of Montana, Broad-based neutralization testing of existing anti-HIV Monoclonal Antibodies at University of Strasbourg, France, Animal Studies of anti-HIV Monoclonal Antibodies at California National Primate Research Center, University of Southern California, Using Artificial Intelligence, identification of additional conserved immutable target sites (epitopes) on the HIV-1 virus and Production of additional Monoclonal Antibodies targeting identified sites (epitopes) on the HIV virus as per a Company

Clinical Trials are fraught with risk and uncertainty. The Company is looking at developing a diverse pipeline of candidates which will help mitigate the risk in case of adverse results or the failure to meet endpoints in any of its ongoing trials of a particular candidate. The success of its clinical trials will help the Company advance its pipeline but it should also be prepared to face any setbacks, in case its trials fail to meet their endpoints.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Click here to please visit our detailed disclosure

References

https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics

https://enzolytics.com/

https://www.globaldata.com/hiv-market-will-see-modest-growth-to-22-5-billion-by-2025-says-globaldata/

https://www.biospace.com/article/releases/enzolytics-inc-completes-merger-with-bioclonetics-immunotherapeutics-inc-/

https://finance.yahoo.com/news/enzolytics-inc-intel-corporation-co-110000244.html

https://stockdaymedia.com/enzolytics-reports-progress-on-its-multiple-therapeutics-platforms-and-initiatives-enzc/